GGrantIndex
← Leaderboards

Joseph Zabner

University Of Iowa

$29,014,505
Attributed
$32,356,820
Total exposure
28
Grants
24
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.1M · FY200525
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$32,356,820 · 28

By mechanism

P01$13,298,519 · 13
R01$6,593,102 · 2
U01$5,326,883 · 1
P30$3,006,840 · 6
P50$2,225,561 · 1
T32$1,394,034 · 1

Top collaborators

Most similar at University Of Iowa

Same institution · by research overlap

Others in their field

Top investigators on “Family Suidae

Research focus

Family SuidaeCystic FibrosisAirway EpitheliumCellsResearch PersonnelEpitheliumLungPhenotypeCystic Fibrosis Transmembrane Conductance RegulatorIn Vitro ModelGene TherapyTissuesFunctional DisorderEvaluationUniversitiesBiological ModelsAnimalsPulmonary Cystic FibrosisInstitutionStudy ModelsResourcesGenerationsCell LineCell Culture Techniques

Grant awards (103)

Project 1$393,848
P01 · FY2025 · HL · contact PI
In Vitro Models and Cell Culture Core$178,795
P01 · FY2024 · HL · contact PI
Cells and Tissue Core-Core 5$156,510
P30 · FY2024 · DK · contact PI
In Vitro Models and Cell Culture Core$185,400
P01 · FY2023 · HL · contact PI
Cells and Tissue Core-Core 5$156,510
P30 · FY2023 · DK · contact PI
Project 3: Contribution of Small Airways to Cystic Fibrosis Lung Disease Pathogenesis$356,949
P01 · FY2022 · HL · contact PI
In Vitro Models and Cell Culture Core$185,400
P01 · FY2022 · HL · contact PI
Cells and Tissue Core-Core 5$156,510
P30 · FY2022 · DK · contact PI
Airway Alkalinization and Repurposing Tromethamine as a Therapeutic Approach in Cystic Fibrosis$1,053,550
R01 · FY2021 · HL
Project 3: Contribution of Small Airways to Cystic Fibrosis Lung Disease Pathogenesis$356,949
P01 · FY2021 · HL · contact PI
In Vitro Models and Cell Culture Core$185,400
P01 · FY2021 · HL · contact PI
Cells and Tissue Core-Core 5$156,510
P30 · FY2021 · DK · contact PI
Airway Alkalinization and Repurposing Tromethamine as a Therapeutic Approach in Cystic Fibrosis$1,054,599
R01 · FY2020 · HL
Multidisciplinary Lung Research Career Development Program$358,242
T32 · FY2020 · HL · contact PI
Project 3: Contribution of Small Airways to Cystic Fibrosis Lung Disease Pathogenesis$356,949
P01 · FY2020 · HL · contact PI
In Vitro Models and Cell Culture Core$185,400
P01 · FY2020 · HL · contact PI
Cells and Tissue Core-Core 5$156,510
P30 · FY2020 · DK · contact PI
Airway Alkalinization and Repurposing Tromethamine as a Therapeutic Approach in Cystic Fibrosis$1,055,623
R01 · FY2019 · HL
Multidisciplinary Lung Research Career Development Program$1,035,792
T32 · FY2019 · HL · contact PI
Project 3: Contribution of Small Airways to Cystic Fibrosis Lung Disease Pathogenesis$356,949
P01 · FY2019 · HL · contact PI
Core C: In Vitro Models and Cell Culture$183,000
P01 · FY2019 · HL · contact PI
Cells and Tissue Core$166,254
P30 · FY2019 · DK · contact PI
Airway Alkalinization and Repurposing Tromethamine as a Therapeutic Approach in Cystic Fibrosis$1,056,522
R01 · FY2018 · HL
Project 3: Contribution of Small Airways to Cystic Fibrosis Lung Disease Pathogenesis$356,949
P01 · FY2018 · HL · contact PI
Core C: In Vitro Models and Cell Culture$183,000
P01 · FY2018 · HL · contact PI
Cells and Tissue Core$167,707
P30 · FY2018 · DK · contact PI
Airway Alkalinization and Repurposing Tromethamine as a Therapeutic Approach in Cystic Fibrosis$1,070,303
R01 · FY2017 · HL
Airway pH and antimocrobial activity in early cystic fibrosis$347,300
P01 · FY2017 · HL · contact PI
Core C: In Vitro Models and Cell Culture$183,000
P01 · FY2017 · HL · contact PI
Cells and Tissue Core$168,185
P30 · FY2017 · DK · contact PI
In Vitro Models and Cell Culture Core$75,500
P01 · FY2017 · HL · contact PI
Airway pH and antimocrobial activity in early cystic fibrosis$347,300
P01 · FY2016 · HL · contact PI
Core C: In Vitro Models and Cell Culture$182,550
P01 · FY2016 · HL · contact PI
Cells and Tissue Core$167,652
P30 · FY2016 · DK · contact PI
In Vitro Models and Cell Culture Core$75,500
P01 · FY2016 · HL · contact PI
Airway pH and antimocrobial activity in early cystic fibrosis$342,996
P01 · FY2015 · HL · contact PI
Core C: In Vitro Models and Cell Culture$181,200
P01 · FY2015 · HL · contact PI
Cells and Tissue Core$166,100
P30 · FY2015 · DK · contact PI
In Vitro Models and Cell Culture Core$71,197
P01 · FY2015 · HL · contact PI
Airway pH and antimocrobial activity in early cystic fibrosis$341,549
P01 · FY2014 · HL · contact PI
Cells and Tissue Core$159,302
P30 · FY2014 · DK · contact PI
In Vitro Models and Cell Culture Core$69,751
P01 · FY2014 · HL · contact PI
Airway pH and antimocrobial activity in early cystic fibrosis$330,630
P01 · FY2013 · HL · contact PI
Directed evolutioni of AAV for gene theraphy in a pig model of cystic fibrosis$269,975
P01 · FY2013 · HL · contact PI
Cell Culture Core$269,974
P01 · FY2013 · HL · contact PI
Cells and Tissue Core$154,605
P30 · FY2013 · DK · contact PI
In Vitro Models and Cell Culture Core$71,874
P01 · FY2013 · HL · contact PI
Ancillary Study 1$2,044,958
U01 · FY2012 · HL · contact PI
Early airway infection in a porcne model of cystic fibrosis$288,090
P01 · FY2012 · HL · contact PI
Cell Culture Core$283,562
P01 · FY2012 · HL · contact PI
Directed evolutioni of AAV for gene theraphy in a pig model of cystic fibrosis$283,561
P01 · FY2012 · HL · contact PI
Cells and Tissue Core$168,880
P30 · FY2012 · DK · contact PI
in Vitro Models and Cell Culture Core$75,062
P01 · FY2012 · HL · contact PI
Ancillary Study 1$2,076,535
U01 · FY2011 · HL · contact PI
Early airway infection in a porcne model of cystic fibrosis$288,090
P01 · FY2011 · HL · contact PI
Cell Culture Core$282,821
P01 · FY2011 · HL · contact PI
Directed evolutioni of AAV for gene theraphy in a pig model of cystic fibrosis$282,820
P01 · FY2011 · HL · contact PI
in Vitro Models and Cell Culture Core$75,062
P01 · FY2011 · HL · contact PI
Ancillary Study 1$1,205,390
U01 · FY2010 · HL · contact PI
Early airway infection in a porcne model of cystic fibrosis$288,090
P01 · FY2010 · HL · contact PI
Cell Culture Core$283,278
P01 · FY2010 · HL · contact PI
Directed evolutioni of AAV for gene theraphy in a pig model of cystic fibrosis$283,278
P01 · FY2010 · HL · contact PI
in Vitro Models and Cell Culture Core$75,059
P01 · FY2010 · HL · contact PI
Request for Funds to Purchase a Replacement Laser Scanning Confocal Microscope$500,000
S10 · FY2009 · RR · contact PI
Cell Culture Core$288,612
P01 · FY2009 · HL · contact PI
Directed evolutioni of AAV for gene theraphy in a pig model of cystic fibrosis$288,612
P01 · FY2009 · HL · contact PI
Early airway infection in a porcne model of cystic fibrosis$288,090
P01 · FY2009 · HL · contact PI
Cells and Tissue Core$168,833
P30 · FY2009 · DK · contact PI
in Vitro Models and Cell Culture Core$75,062
P01 · FY2009 · HL · contact PI
Interactions of AAV5 with Sialic Acid and PDGF Receptors$333,915
P01 · FY2008 · HL · contact PI
Early airway infection in a porcne model of cystic fibrosis$288,090
P01 · FY2008 · HL · contact PI
Core-- Administration$120,620
P01 · FY2008 · HL · contact PI
in Vitro Models and Cell Culture Core$75,062
P01 · FY2008 · HL · contact PI
Xylitol Enhancement of Bacterial Killing by Airway$430,308
P50 · FY2007 · HL · contact PI
Interactions of AAV5 with Sialic Acid and PDGF Receptors$330,839
P01 · FY2007 · HL · contact PI
Ligand-Receptor Segregation and Airway Remodeling$314,678
R01 · FY2007 · HL · contact PI
Core-- Administration$119,725
P01 · FY2007 · HL · contact PI
Ligand-Receptor Segregation and Airway Remodeling$324,077
R01 · FY2006 · HL · contact PI
Xylitol Enhancement of Bacterial Killing by Airway$268,740
P50 · FY2006 · HL · contact PI
Interactions of AAV5 with Sialic Acid and PDGF Receptors$206,916
P01 · FY2006 · HL · contact PI
Core-- Administration$74,997
P01 · FY2006 · HL · contact PI
SAFETY OF AEROSOLIZED XYLITOL IN SUBJECTS WITH CYSTIC FIBROSIS$2,316
M01 · FY2006 · RR · contact PI
Ligand-Receptor Segregation and Airway Remodeling$331,875
R01 · FY2005 · HL
Xylitol Enhancement of Bacterial Killing by Airway$261,412
P50 · FY2005 · HL
Interactions of AAV5 with Sialic Acid and PDGF Receptors$200,891
P01 · FY2005 · HL
Core-- Administration$72,937
P01 · FY2005 · HL
BRONCHOSCOPIC ASSESSMENT OF AIRWAY RETENTION TIME OF AEROSOLIZED XYLITOL$5,180
M01 · FY2005 · RR
Ligand-Receptor Segregation and Airway Remodeling$331,875
R01 · FY2004 · HL
Xylitol Enhancement of Bacterial Killing by Airway$253,313
P50 · FY2004 · HL
Interactions of AAV5 with Sialic Acid and PDGF Receptors$195,025
P01 · FY2004 · HL
Core-- Administration$72,541
P01 · FY2004 · HL
Effect of Ionic Versus Non-Ionic Osmolytes in the Airway$3,373
M01 · FY2004 · RR
Bronchoscopic Assessment of Airway Retention Time$1,012
M01 · FY2004 · RR
Xylitol Enhancement of Bacterial Killing by Airway$231,687
P50 · FY2003 · HL
CORE--CELLS AND TISSUES$296,752
P30 · FY2002 · DK
IMPROVED EFFICACY OF ADENOVIRUS MEDIATED GENE TRANSFER TO AIRWAY EPITHELIA$290,033
P01 · FY2002 · HL
ELECTROLYTE COMPOSITION OF SURFACE FLUID IN NORMAL AND CF AIRWAY EPITHELIA$243,516
P50 · FY2002 · HL
CORE--CELLS AND TISSUES$296,752
P30 · FY2001 · DK
IMPROVED EFFICACY OF ADENOVIRUS MEDIATED GENE TRANSFER TO AIRWAY EPITHELIA$290,033
P01 · FY2001 · HL
ELECTROLYTE COMPOSITION OF SURFACE FLUID IN NORMAL AND CF AIRWAY EPITHELIA$243,516
P50 · FY2001 · HL
ELECTROLYTE COMPOSITION OF SURFACE FLUID IN NORMAL AND CF AIRWAY EPITHELIA$293,069
P50 · FY2000 · HL
IMPROVED EFFICACY OF ADENOVIRUS MEDIATED GENE TRANSFER TO AIRWAY EPITHELIA$272,462
P01 · FY2000 · HL
CORE--CELLS AND TISSUES$143,268
P30 · FY2000 · DK